Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
It is a dual agonist, working on both the GLP-1 and GIP receptors, making it a promising candidate in the field of obesity and diabetes research
Acknowledgements This work was funded in part by Science Foundation Ireland Principal Investigator Award (11/PI/1188) to SD
In one long-term study, called the SURMOUNT-1 trial, people taking tirzepatide lost up to 25% of their starting weight over a period of 72 weeks
H tr thi c gim m tha
Other UTSW researchers who contributed to the study are Assistant Professor of Internal Medicine Laurent Gautron, Ph.D., and Research Technicians Bryan Portillo, B.S., Kyle Grose, B.S., and Jason Ajwani, B.S
US$ 24.36
US$ 22.64
US$ 22.29
US$ 28.01
US$ 22.08
US$ 22.73
